ArticleMicrobiology spectrum2022
Molecular Cut-off Values for Aliarcobacter butzleri Susceptibility Testing.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Long-read metagenomics and methylation-based binning support the discovery of antibiotic resistance gene-host associations in complex communities.Genome biology · 2026Article
- Functional Stability of Tetracycline: Practical Information for Its Use in Bacterial Selection.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Construction and characterization of the first Arcobacter butzleri - Escherichia coli shuttle vector.Archives of microbiology · 2026Article
- The microbiological and clinical characteristics of 1,204 human cases of Aliarcobacter spp. infections that occurred in France between 2002 and 2024.Gut pathogens · 2025Article
- Evaluation of agar dilution as an alternative method for antimicrobial susceptibility testing and tentative ECOFF determination for Arcobacter butzleri.Scientific reports · 2025Article
- Acute gastroenteritis due to Arcobacter butzleri: an emerging pathogen.Gut pathogens · 2025Article
- Review
- Virulence genotype and phenotype of two clinical isolates of Arcobacter butzleri obtained from patients with different pathologies.Archives of microbiology · 2023Article
- Genomic Characterization of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Antibiotic Resistance in Selected Emerging Bacterial Foodborne Pathogens-An Issue of Concern?Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aliarcobacter butzleri is an emerging gastrointestinal pathogen found in many countries worldwide. In France, it has become the third most commonly isolated bacterial species from the stools of patients with intestinal infections. No interpretative criteria for antimicrobial susceptibility testing have been proposed for A. butzleri, and most strains are categorized using the recommendations of the Clinical and Laboratory Standards Institute or the European Committee on Antimicrobial Susceptibility Testing for Campylobacter or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.